Agreeing to significant financial terms, Janssen Biotech has exercised its option to collaborate with Idorsia Pharmaceuticals to co-develop and commercialise aprocitentan in return for a one-time milestone payment of US$230 M and extremely high royalty rates upon commercialisation. Aprocitentan is being developed for resistant hypertension, a condition that puts patients at a higher risk of cardiovascular disease.